Oncology - Physician's Channel - Mount Sinai New York

Skip to main content

Gain valuable insights from The Tisch Cancer Institute at Mount Sinai—a National Cancer Institute-designated cancer center and an integral part of the Mount Sinai Tisch Cancer Center—and cancer specialists throughout the Mount Sinai Health System. Our extensive network spans cancer prevention, innovative developments in precision-medicine and immunotherapy approaches, novel treatments via clinical trials, equity in cancer care, and groundbreaking translational research.

Under the leadership of Ramon Parsons, MD, PhD, Joseph A. Sparano, MD, and Luis Isola, MD, our comprehensive cancer program is renowned for its powerful synergy between research scientists and clinicians and its multidisciplinary scope. The Mount Sinai Hospital's Department of Oncology is nationally ranked by U.S. News & World Report.

Gain valuable insights from The Tisch Cancer Institute at Mount Sinai—a National Cancer Institute-designated cancer center and an integral part of the Mount Sinai Tisch Cancer Center—and cancer specialists throughout the Mount Sinai Health System. Our extensive network spans cancer prevention, innovative developments in precision-medicine and immunotherapy approaches, novel treatments via clinical trials, equity in cancer care, and groundbreaking translational research.

Under the leadership of Ramon Parsons, MD, PhD, Joseph A. Sparano, MD, and Luis Isola, MD, our comprehensive cancer program is renowned for its powerful synergy between research scientists and clinicians and its multidisciplinary scope. The Mount Sinai Hospital's Department of Oncology is nationally ranked by U.S. News & World Report.

Refer a Patient Online

Or call 212-241-4983

Find A Specialist

Latest Videos

Ramon Parsons, MD, PhD, explains PTEN and cancer

Ramon Parsons, MD, PhD, explains PTEN and cancer

A Department of Medicine Grand Rounds presented by Ramon Parsons, MD, PhD, Director, The Tisch Cancer Institute, and Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai

Luis M. Isola, MD, discusses fighting hematological cancers

Luis M. Isola, MD, discusses fighting hematological cancers

A profile of Luis M. Isola, MD, Director of Cancer Clinical Programs, Mount Sinai Health System

Steven J. Burakoff, MD, looks to the future of cancer care

Steven J. Burakoff, MD, looks to the future of cancer care

A profile of Steven J. Burakoff, MD, Dean for Cancer Innovation at the Icahn School of Medicine at Mount Sinai and Chief of Pediatric Oncology at the Mount Sinai Health System

Pursuing Progress, Precision, and Equity in Cancer Care

Pursuing Progress, Precision, and Equity in Cancer Care

With a particular focus on breast cancer, Dr. Sparano presents on progress in reducing mortality, advancing precision medicine for improved outcomes, and addressing disparities in care and outcomes.

Mount Sinai Researchers Find Spaceflight May Be Associated With DNA Mutations and Increased Risk of Developing Heart Disease and Cancer

Mount Sinai Researchers Find Spaceflight May Be Associated With DNA Mutations and Increased Risk of Developing Heart Disease and Cancer

Mount Sinai study could lead to ongoing health monitoring of astronauts to assess possible health risks and prevent disease progression.

Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors

Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking ...

Mount Sinai Cardio-Oncology Program Receives Highest Designation for Excellence

Mount Sinai Cardio-Oncology Program Receives Highest Designation for Excellence

The Cardio-Oncology Program at The Mount Sinai Hospital, under the directorship of Gagan Sahni, MD, has been awarded Gold Center of Excellence status. This is the highest designation of certification from the International Cardio-Oncology ...

Institutional Perspective in Cancer – GI: Chaired by Deirdre Cohen, MD

Institutional Perspective in Cancer – GI: Chaired by Deirdre Cohen, MD

This session on cancers of the GI tract, hosted by OncLive, provides an update on how Mount Sinai is treating patients with the most current therapies

Mount Sinai Study finds Biomarker in Liquid Biopsy for Lung Cancer Appears More Accurate in Predicting Immunotherapy Response Than Tumor Biopsy

Mount Sinai Study finds Biomarker in Liquid Biopsy for Lung Cancer Appears More Accurate in Predicting Immunotherapy Response Than Tumor Biopsy

Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.

Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates

Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle...

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure for Myerlofibrosis: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure for Myerlofibrosis: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Improvement in spleen and symptom burden with fedratinib therapy for patients with myelofibrosis

Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care

Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care

The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued ...

Mount Sinai Scientists discover gene mutation that signals aggressive melanoma

Mount Sinai Scientists discover gene mutation that signals aggressive melanoma

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

A subset of blood cancer patients still remained vulnerable, needing fourth dose or antibody treatments

Lung Scans Reveal Elevated Incidence of Liver Disease Among 9/11 First Responders

Lung Scans Reveal Elevated Incidence of Liver Disease Among 9/11 First Responders

World Trade Center (WTC) first responders who underwent low-dose CT (computed tomography) lung screenings were three times more likely to have moderate-to-severe steatosis than others, a result much higher than expected.

Deciphering the Mechanism of Resistance to CDK4/6 Inhibitors in Multiple Tumor Types

Deciphering the Mechanism of Resistance to CDK4/6 Inhibitors in Multiple Tumor Types

Small-molecule inhibitors of the closely related cyclin-dependent kinases 4 and 6 (CDK4/6 is) that have shown success in treating patients with metastatic breast cancer have been only modestly effective against other tumor types.

A Novel Target for Treating Early Stage Lung Cancer

A Novel Target for Treating Early Stage Lung Cancer

Scientists led by Miriam Merad, MD, PhD, have shown for the first time that specific populations of macrophages promote tumor growth and contribute to immune evasion in early lung cancer lesions.

Identifying Lead Compounds That Effectively Treat Liver Cancer

Identifying Lead Compounds That Effectively Treat Liver Cancer

The search for effective new treatments for liver cancer has led Mount Sinai investigators to highly targeted compound libraries that include kinase inhibitors, histone modifying enzymes, and other small molecules used in combination with ...

Destroying Acute Myeloid Leukemia Cells With a Novel Antibody-Led Regimen

Destroying Acute Myeloid Leukemia Cells With a Novel Antibody-Led Regimen

Acute myeloid leukemia manages to cleverly evade the surface markers that the immune system recognizes in order to attack malignant cells.

A Promising Strategy for Preventing Cancer Metastasis and Enhancing Dormancy

A Promising Strategy for Preventing Cancer Metastasis and Enhancing Dormancy

A research team at The Tisch Cancer Institute, which focuses on the burgeoning field of cancer dormancy, has identified a promising strategy for preventing metastasis from occurring.

Improving Immunotherapy Outcomes Through "Bystander Killing"

Improving Immunotherapy Outcomes Through "Bystander Killing"

One major limitation of T-cell-based immunotherapies is a phenomenon known as “antigen escape,” which occurs when a subset of cancer cells lose the targeted antigen.

New Approaches to Developing Personalized Cancer Vaccines

New Approaches to Developing Personalized Cancer Vaccines

Investigators at The Tisch Cancer Institute are developing different types of personalized vaccines, including those that treat cancers with common cell mutations and those combined with checkpoint inhibitors.

Three Compounds Offer Hope in the Battle Against Mantle Cell Lymphoma

Three Compounds Offer Hope in the Battle Against Mantle Cell Lymphoma

Mount Sinai researchers led by Samir Parekh, MD, have found a family of three compounds that fit into a pocket on the SOX11 surface that interfere with DNA binding and block the mechanism by which mantle cell lymphoma develops.

Mount Sinai Gets New Chief of Pediatric Hematology-Oncology

Mount Sinai Gets New Chief of Pediatric Hematology-Oncology

Oren J. Becher, MD, was recently named Chief of the Jack Martin Division of Pediatric Hematology-Oncology, the Steven Ravitch Chair in Pediatric Hematology, and Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai.

An Engineered Molecule, MS21, Slows the Growth of Multiple Tumor Types

An Engineered Molecule, MS21, Slows the Growth of Multiple Tumor Types

Investigators Ramon Parsons, MD, PhD, and Jian Jin, PhD, have engineered a synthetic compound—a small molecule called MS21— that targets the PTEN/AKT pathway, one of the most commonly mutated pathways in human cancers.

The Adjuvant Use of Immunotherapy for Bladder Cancer

The Adjuvant Use of Immunotherapy for Bladder Cancer

The U.S. Food and Drug Administration's recent approval of the adjuvant use of nivolumab for muscle-invasive urothelial carcinoma may set a new standard of care.

Renowned Clinician Researcher Joseph A. Sparano, MD, Joins Mount Sinai

Renowned Clinician Researcher Joseph A. Sparano, MD, Joins Mount Sinai

In June 2021, clinician and researcher, Joseph A. Sparano, MD, joined The Tisch Cancer Institute as Deputy Director, where he will continue to lead clinical trials and improve treatments for breast cancer and cancers associated with HIV ...

A Message From Director Ramon Parsons, MD, PhD

A Message From Director Ramon Parsons, MD, PhD

We begin 2022 with a look at The Tisch Cancer Institute’s (TCI) latest discoveries by highlighting the work of our dedicated investigators. Their advances will bring our patients better health and longevity.

Gene Signatures May Predict Outcomes Among Similar-Appearing Tumors

Gene Signatures May Predict Outcomes Among Similar-Appearing Tumors

Gene signatures derived from lung carcinoma could potentially predict outcomes among individuals with small lung cancers detected by chest CT imaging, when those tumors cannot be distinguished visually as aggressive or indolent.

Building a Hub to Catch Lung Cancer Early

Building a Hub to Catch Lung Cancer Early

Fewer than 10 percent of potentially eligible patients undergo lung cancer screening, resulting in unnecessary illness and death. The new Chief of Pulmonary, Critical Care and Sleep Medicine at Mount Sinai Morningside wants to change that.

Decline in Lung Cancer Deaths Is Linked to Increased Screening

Decline in Lung Cancer Deaths Is Linked to Increased Screening

A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, a new study shows.

PD-L1 Expression: Practical Implications in Lung Cancer

PD-L1 Expression: Practical Implications in Lung Cancer

Tapping into the predictive capability of PD-L1 expression in Non-Small Cell Lung Cancer

The Tisch Cancer Institute Specialty Report 2022

The Tisch Cancer Institute Specialty Report 2022

We begin 2022 with a look at The Tisch Cancer Institute’s (TCI) latest discoveries. In this report we highlight the work of our dedicated investigators who explore the complexity of cancer formation and metastasis and search for effective ways to stop it.

Mount Sinai Finds Lung Cancer Death Decline Associated With Screening, Earlier Diagnosis, and Surgery

Mount Sinai Finds Lung Cancer Death Decline Associated With Screening, Earlier Diagnosis, and Surgery

A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, supporting the need for increased use of screening to save lives, according to a Mount Sinai study published in JAMA ...

Lung screening at Mount Sinai leads to early detection of lung cancer in former smoker

Lung screening at Mount Sinai leads to early detection of lung cancer in former smoker

Growing up in Austria, Wolfgang Lehner was a heavy, pack-a-day smoker from age 15 to 51. He quit smoking in 2010.

Pancreatic Cancer: Current Challenges and Future Directions

Pancreatic Cancer: Current Challenges and Future Directions

Dr. Cohen describes current challenges in the treatment of pancreatic cancer and provides evidence for emerging treatment paradigms

Researchers Identify New Drug Target for Blood Cancer, Potentially Solid Tumors

Researchers Identify New Drug Target for Blood Cancer, Potentially Solid Tumors

Findings are being used to create a clinical trial for patients with myelodysplastic syndrome

Childhood Brain Tumor Expert Named Chief of Pediatric Hematology-Oncology at Mount Sinai Kravis Children’s Hospital

Childhood Brain Tumor Expert Named Chief of Pediatric Hematology-Oncology at Mount Sinai Kravis Children’s Hospital

Dr. Becher is an expert in brain tumors in children, particularly diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain cancer. For more than a decade, his research has focused on identifying therapeutic targets to treat DIPG.

Mount Sinai Scientists Show That a Novel Therapy Could Be Effective Against Pediatric Leukemia

Mount Sinai Scientists Show That a Novel Therapy Could Be Effective Against Pediatric Leukemia

Therapy could also fight pancreatic and other cancers, researchers say

$60 million pledged to establish the Mount Sinai Tisch Cancer Center and to construct a state-of-the-art cancer hospital in Manhattan

$60 million pledged to establish the Mount Sinai Tisch Cancer Center and to construct a state-of-the-art cancer hospital in Manhattan

Cholangiocarcinoma: Bridging the Gap Between the Clinic and the Laboratory

Cholangiocarcinoma: Bridging the Gap Between the Clinic and the Laboratory

This presentation highlights the epidemiology and current management of cholangiocarcinoma, as well as future therapeutic approaches

Joseph Sparano, MD, leads Hematology and Medical Oncology and is Deputy Director of The Tisch Cancer Institute

Joseph Sparano, MD, leads Hematology and Medical Oncology and is Deputy Director of The Tisch Cancer Institute

Internationally Renowned Breast Cancer and HIV-Associated Malignancy Expert to Join Mount Sinai

Not Every Patient With HCC is the Same: The Need for More Equitable Liver Cancer Screening

Not Every Patient With HCC is the Same: The Need for More Equitable Liver Cancer Screening

Liver Cancer Screening Guidelines Miss Many Black Patients

Center of Excellence for Liver and Bile Duct Cancer

Center of Excellence for Liver and Bile Duct Cancer

Leader in Liver and Bile Duct Cancers

Early Lung Cancer Coopts Immune Cell Into Helping Tumors Invade the Lungs, Mount Sinai Researchers Discover

Early Lung Cancer Coopts Immune Cell Into Helping Tumors Invade the Lungs, Mount Sinai Researchers Discover

Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in Nature.

Bladder Cancer Treatment Without Cystectomy

Bladder Cancer Treatment Without Cystectomy

Matthew Galsky, MD, reported at the 2021 ASCO annual meeting that transurethral resection of bladder tumor + gemcitabine, cisplatin, plus nivolumab achieves stringently defined clinical complete response in a large subset of patients with ...

Anti-HER2 Treatments Can Cause Pulmonary Toxicities in HER2+ Breast Cancer

Anti-HER2 Treatments Can Cause Pulmonary Toxicities in HER2+ Breast Cancer

Charles Powell, MD, System Chief for Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine and CEO of the Mount Sinai-National Jewish Health Respiratory Institute, answers questions regarding anti-HER2 monoclonal ...

Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA

Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA

Dr. Matthew Galsky and colleagues identify genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder

NYEE’s Ocular Oncology Service Expanded Patient Options for Eye Cancer Treatment

NYEE’s Ocular Oncology Service Expanded Patient Options for Eye Cancer Treatment

The Ocular Oncology Service at NYEE is home to the most advanced forms of eye cancer treatments aimed at preserving life, preserving the eye, and saving sight

Make a Referral

Call
212-241- 4983

Find A Specialist